BUDA Buda Juice Inc

$BUDA just got fresh coverage from Roth/MKM. Buy rating, $12 target, that's the same level as its 52-week high. Stock's been as low as $6.25 this year, so Wall Street is pointing at a real round trip if the Texas cold-press playbook expands. MACD just flipped bullish too. 👀

Roth/MKM initiated coverage of Buda Juice, a producer of cold-pressed juices, with a Buy rating and a $12.00 price target, implying significant upside from current levels. Analyst George Kelly highlighted the company's differentiated end-to-end cold-chain supply network and strong sales velocities in its home Texas market as key pillars of the investment thesis. Kelly also pointed to Buda Juice's fresh, unpasteurized products, which are sold at competitive prices in the produce sections of major supermarkets and operate in a relatively uncrowded niche. The company now has capital from its IPO to replicate its Texas strategy in new markets. The $12 target matches the stock's 52-week high, suggesting Roth/MKM sees potential for a recovery to previous highs. The stock has traded as low as $6.25 over the past year, while the new coverage provides investors with a formal Wall Street framework for the company's expansion strategy. $BUDA